Ketamine Modulates Gut-Brain-Lung Communication Pathways

Ketamine’s Second Act: How an Anesthetic Modulates Gut-Brain-Lung Communication

Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, produces rapid antidepressant effects within hours, a timeline that challenges conventional theories of depression treatment. A 2026 review in Molecular Psychiatry from researchers at Huazhong University of Science and Technology and Chiba University consolidates evidence for a surprising mediator of these effects: the gut microbiome. The work suggests ketamine and its enantiomers exert significant anti-inflammatory and organ-protective actions by interacting with gut bacteria, microbial metabolites, and immune cell trafficking along the gut-brain and gut-lung axes. This positions the gut as a potential target and modifier of ketamine’s therapeutic profile.

The Direct Brain Effects of Ketamine Are Just One Pathway

For decades, ketamine’s primary mechanism was attributed to its blockade of NMDARs in the brain, leading to a surge in glutamate and synaptic plasticity. This direct central action remains its most well-established pathway. However, the review led by Zhao, Zhang, and Hashimoto argues that focusing solely on the brain provides an incomplete picture. Significant portions of ketamine’s systemic anti-inflammatory and sustained benefits may originate in the intestine. Distinguishing these gut-mediated pathways from direct neurological actions is essential for understanding the drug’s full therapeutic potential and its side effects.

Gut Microbiota as a Pharmacological Target

Ketamine administration is consistently associated with changes in microbial composition. Studies cited in the review show treatment can restore a more balanced community of gut bacteria, often increasing the abundance of beneficial species linked to anti-inflammatory states. A primary consequence of this shift is the normalization of short-chain fatty acid (SCFA) levels. SCFAs like butyrate are microbial metabolites known to strengthen the intestinal barrier, regulate immunity, and signal directly to the brain. By modulating the microbiota, ketamine may indirectly boost production of these protective compounds.

Blocking a Pro-Inflammatory Highway from Gut to Brain

Perhaps the most direct gut-brain link involves immune cells. The intestinal lining is a major reservoir for specialized immune cells, including γδ T17 and T-helper 17 (Th17) cells. Under conditions of dysbiosis and increased intestinal permeability—sometimes called “leaky gut”—these pro-inflammatory cells can migrate from the gut to the meninges and brain tissue. The review summarizes evidence that ketamine reduces this migration. Lower numbers of gut-derived Th17 cells in the central nervous system correlate strongly with attenuated neuroinflammation and reduced depressive-like behaviors in animal models. This identifies a clear cellular pathway connecting gut health to mood regulation.

Arketamine vs. Esketamine: Enantiomers with Different Gut Interactions

Ketamine exists as two mirror-image molecules: (S)-ketamine (esketamine) and (R)-ketamine (arketamine). Esketamine has a stronger affinity for the NMDAR and is the form approved for treatment-resistant depression. The review notes, however, that arketamine appears to provide more sustained neuroprotective and antidepressant effects in preclinical studies, potentially with fewer dissociative side effects. The authors propose these differences may be partly rooted in how each enantiomer interacts with the gut ecosystem. Arketamine might promote a more resilient and anti-inflammatory microbial profile, leading to longer-lasting modulation of the gut-brain axis. This enantiomer-specificity requires confirmation in human trials but suggests future therapies could be refined based on gut microbiome responses.

The Gut-Lung Axis: Ketamine’s Role in Systemic Inflammation

The communication network extends beyond the brain. The gut-lung axis describes the bidirectional influence between the intestinal microbiome and respiratory health. In critical illness, such as acute lung injury, gut barrier failure can allow bacteria or bacterial products to translocate into the mesenteric lymph system, triggering a damaging systemic inflammatory response that harms the lungs. The review indicates ketamine may help limit this process. Evidence points to ketamine reducing bacterial translocation, dampening inflammatory signaling in the lymph, and decreasing the infiltration of pro-inflammatory cells into lung tissue. This positions the drug as a potential modulator of multi-organ failure in sepsis or acute respiratory distress syndrome, though clinical applications here are still investigational.

Practical Implications and Cautious Optimism

These findings broaden the therapeutic horizon for ketamine beyond psychiatry. The potential to treat conditions characterized by inflammation, barrier dysfunction, and immune dysregulation—such as certain autoimmune diseases or post-severe infection syndromes—becomes plausible. For mental health, it strengthens the argument for an integrated treatment approach. A therapy targeting the gut-brain axis, such as specific psychobiotics, might be considered alongside ketamine treatment to potentially enhance or prolong its benefits.

Microbiome Health as a Treatment Modifier

The state of a patient’s gut microbiome could influence their response to ketamine. An individual with significant dysbiosis or small intestinal bacterial overgrowth (SIBO) might have a different therapeutic outcome compared to someone with a more resilient microbial community. This underscores the value of supporting foundational gut health through diet and lifestyle, which may improve treatment efficacy for various conditions. Our guide to gut health supplements details evidence-based approaches to microbiome support.

Acknowledging Limitations and the Causality Gap

The review authors emphasize a critical limitation: much of the evidence linking ketamine to gut-mediated effects comes from animal studies. Establishing clear causality in humans is complex. Does ketamine improve mood by fixing the gut, or does improving mood (and reducing stress) subsequently heal the gut? The relationships are likely bidirectional. Furthermore, long-term effects of repeated ketamine exposure on the human microbiome are unknown. Potential risks, including dependency and urinary tract toxicity, remain serious concerns that are not mitigated by its gut actions.

Future Research Directions

Next steps require meticulous human studies. Researchers need to profile the gut microbiome of patients before and after ketamine treatment, correlating shifts with clinical outcomes. Controlled trials comparing arketamine and esketamine, with parallel microbiome analysis, could clarify enantiomer-specific effects. Investigating whether prebiotic fibers or probiotics can augment ketamine’s efficacy or durability represents a logical clinical question. Finally, exploring these gut-organ axes could lead to novel, non-psychoactive compounds designed specifically to modulate these pathways for inflammatory diseases.

Key Takeaways

• Ketamine’s rapid antidepressant effects involve more than direct brain receptor blockade; significant anti-inflammatory action is mediated through the gut microbiome and immune system.
• The drug helps restore microbial balance, increases beneficial short-chain fatty acids, and reduces the migration of pro-inflammatory gut immune cells to the brain.
• Ketamine’s (R)-enantiomer, arketamine, may offer more sustained benefits with potentially fewer side effects than the approved (S)-enantiomer, esketamine, possibly due to different gut interactions.
• Through the gut-lung axis, ketamine shows potential to limit systemic inflammation and organ damage in critical illnesses like acute lung injury, expanding its possible therapeutic uses.
• A patient’s baseline gut health may influence their response to ketamine, supporting a holistic treatment approach that includes microbiome care.
• Current evidence is heavily based on preclinical models; human studies are needed to confirm causality and long-term safety of these gut-mediated pathways.
• The discovery underscores the fundamental role of the gut-brain axis in mental health and systemic inflammation, validating it as a major target for future therapies.

This article is for informational purposes only. Consult a qualified professional for personalised advice.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41974884/
https://pubmed.ncbi.nlm.nih.gov/41967815/
https://pubmed.ncbi.nlm.nih.gov/41961405/